INNATE PHARMA SA-SPONS ADR (IPHA:NASDAQ)
$1.51 -0.08 (-5.0314%)
Analysed INNATE PHARMA SA-SPONS ADR (IPHA:NASDAQ) News Sources
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
17-04-2026
yahoo.com
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
13-04-2026
yahoo.com
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
13-04-2026
yahoo.com
Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event
08-04-2026
yahoo.com
Innate Pharma to Participate in the Kempen Life Sciences Conference
03-04-2026
yahoo.com
Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report
02-04-2026
yahoo.com
How Innate Pharma (ENXTPA:IPH) Story Is Shifting Around 2026 Catalysts And €8 Target
27-03-2026
yahoo.com
Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...
26-03-2026
yahoo.com
Innate Pharma Q4 Earnings Call Highlights
26-03-2026
marketbeat.com
Innate Pharma Reports Full Year 2025 Financial Results and Business Update
26-03-2026
yahoo.com
What is the current price of INNATE PHARMA SA-SPONS ADR (IPHA:NASDAQ)?
The current price of INNATE PHARMA SA-SPONS ADR (IPHA:NASDAQ) is $1.51.
INNATE PHARMA SA-SPONS ADR (IPHA:NASDAQ) absolute price change since previous trading day?
The absolute price change of INNATE PHARMA SA-SPONS ADR (IPHA:NASDAQ) since the previous trading day is $-0.08.
INNATE PHARMA SA-SPONS ADR (IPHA:NASDAQ) percentage price change since previous trading day?
The percentage price change of INNATE PHARMA SA-SPONS ADR (IPHA:NASDAQ) since the previous trading day is -5.0314%.
What is the most recent average sentiment score for INNATE PHARMA SA-SPONS ADR (IPHA:NASDAQ)?
The most recent average sentiment score for INNATE PHARMA SA-SPONS ADR (IPHA:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for INNATE PHARMA SA-SPONS ADR (IPHA:NASDAQ)?
The most recent sentiment for INNATE PHARMA SA-SPONS ADR (IPHA:NASDAQ) is .
SEC-8K** Filing Available For INNATE PHARMA SA-SPONS ADR (IPHA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.